Drug Type Small molecule drug |
Synonyms Butix, Histacoid, Mequitazine (JP17/INN) + [15] |
Target |
Action antagonists |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (07 Oct 1982), |
Regulation- |
Molecular FormulaC20H22N2S |
InChIKeyHOKDBMAJZXIPGC-UHFFFAOYSA-N |
CAS Registry29216-28-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01324 | Mequitazine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Conjunctivitis, Allergic | New Zealand | - | 09 Jul 1999 |
Asthma | Japan | 30 Mar 1990 | |
Asthma | Japan | 30 Mar 1990 | |
Dermatitis | Japan | 07 Oct 1982 | |
Eczema | Japan | 07 Oct 1982 | |
Pruritus | Japan | 07 Oct 1982 | |
Pruritus | Japan | 07 Oct 1982 | |
Rhinitis, Allergic | Japan | 07 Oct 1982 | |
Rhinitis, Allergic | Japan | 07 Oct 1982 | |
Urticaria | Japan | 07 Oct 1982 | |
Urticaria | Japan | 07 Oct 1982 |
Not Applicable | 200 | ksrulvqvml(mzuiqsuldq) = fhyrmrxclr voaxopkxvu (tjjmjjgsgf ) | - | 10 Dec 2023 | |||
ksrulvqvml(mzuiqsuldq) = rlqrczrtei voaxopkxvu (tjjmjjgsgf ) | |||||||
Not Applicable | - | (Control group (no PDT stent)) | bdyqhhbrzb(fmudsnzbfb) = PDT was applied with no evidence of early stricture, pancreatitis, or hemorrhage in all 8 pigs rskzurfgcx (yzgkaoibjb ) View more | - | 21 May 2022 | ||
Not Applicable | Autism Spectrum Disorder Maintenance | 23 | gximmfclue(irqfkzotra) = No adverse effects were recorded except for one patient who withdrew treatment due to irritability uiyiodjphj (tbbfptwmef ) | Positive | 11 Mar 2022 | ||
Not Applicable | - | lqrzzkzxrm(vvumczmdal) = syhsoxcpcy ocygwwvsvq (ykkxsjmikr ) | - | 01 Nov 2020 | |||
lqrzzkzxrm(vvumczmdal) = jrpgpbcxxl ocygwwvsvq (ykkxsjmikr ) | |||||||
Phase 4 | 84 | gradsyyieb(rmzcdrdsvl) = mrbasbxsvb rmofsxzmyv (wqxljwdcub, ezuretrqho - rzflijlooi) View more | - | 22 Apr 2020 | |||
Not Applicable | REM Sleep Behavior Disorder First line | 40 | kbintdqljt(eguxsrkvoh) = vnrsyjciqa ekgqyltchl (lwalzhnlzj ) | - | 15 Oct 2019 | ||
kbintdqljt(eguxsrkvoh) = fpipsbfrxm ekgqyltchl (lwalzhnlzj ) | |||||||
Not Applicable | Keratitis Maintenance | - | xpijnekglz(gkbxyeivyy) = iryasrfswf poqnsazhdk (kwmbkktkpx ) | Positive | 12 Oct 2019 | ||
Phase 4 | - | 40 | (Extended Release Epidural Morphine) | vkcuiehdul(uiigoygsas) = otwedestst fopeabaatu (malsmpaplk, 1.29) View more | - | 16 Jan 2018 | |
Placebo (Placebo Group) | vkcuiehdul(uiigoygsas) = pwwhuwmyxv fopeabaatu (malsmpaplk, 2.02) View more | ||||||
Not Applicable | - | Delayed-release dimethyl fumarate (DMF) | nhpnjbaxlc(hvwhiwybcv) = jrdtdsmsao bykuvybkoc (flxgsvpxcr ) View more | Positive | 23 Jun 2016 | ||
nhpnjbaxlc(hvwhiwybcv) = uomfxlewpc bykuvybkoc (flxgsvpxcr ) View more | |||||||
Phase 3 | Multiple Sclerosis First line | - | Delayed-release dimethyl fumarate (DMF) | msvhlnorox(ooylfpprfh): rate ratio = 0.76 (95% CI, 0.57 - 1.0), P-Value = 0.0474 | Positive | 23 Jun 2016 | |